Direct interaction of sox10 with the promoter of murine Dopachrome tautomerase (Dct) and synergistic activation of Dct expression with mitf

被引:80
作者
Jiao, ZX
Mollaaghababa, R
Pavan, WJ
Antonellis, A
Green, ED
Hornyak, TJ
机构
[1] Henry Ford Hlth Syst, Dept Dermatol, Detroit, MI USA
[2] NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA
[3] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA
来源
PIGMENT CELL RESEARCH | 2004年 / 17卷 / 04期
关键词
melanocyte; Mitf; Sox10; transcription; dopachrome tautomerase; tyrosinase-related protein-2; neural crest;
D O I
10.1111/j.1600-0749.2004.00154.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The murine dopachrome tautomerase (Dct) gene is expressed early in melanocyte development during embryogenesis, prior to other members of the tyrosinase gene family important for regulating pigmentation. We have used deletion mutants of the Dct promoter, transfections with developmentally relevant transcription factors, and gel shift assays to define transcriptional determinants of Dct expression. Deletion mutagenesis studies show that sequences within the proximal 459 nucleotides are critical for high level expression in melanocytic cells. This region of the promoter contains candidate binding sites for the transcription factors Sox10 and Mitf. Transfections into 293T and NIH3T3 cells show that Sox10 and Mitf independently activate Dct expression, and, when co-transfected, synergistically activate Dct expression. To support the notion that Sox10 acts directly upon the Dct promoter to activate gene expression, direct interaction of Sox10 was demonstrated using gel shifts of oligonucleotide probes derived from promoter sequences within the region required for Sox10-dependent induction. These results suggest that a combinatorial transcription factor interaction is important for expression of Dct in neural crest-derived melanocytes, and support a model for sequential gene activation in melanocyte development whereby Mitf, a Sox10-dependent transcription factor, is expressed initially before an early melanocyte differentiation gene, Dct, is expressed.
引用
收藏
页码:352 / 362
页数:11
相关论文
共 45 条
[1]   Identification of a composite enhancer of the human tyrosinase-related protein 2/DOPAchrome tautomerase gene [J].
Amae, S ;
Yasumoto, K ;
Takeda, K ;
Udono, T ;
Takahashi, K ;
Shibahara, S .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2000, 1492 (2-3) :505-508
[2]   Different cis-acting elements are involved in the regulation of TRP1 and TRP2 promoter activities by cyclic AMP:: Pivotal role of M boxes (GTCATGTGCT) and of microphthalmia [J].
Bertolotto, C ;
Buscà, R ;
Abbe, P ;
Bille, K ;
Aberdam, E ;
Ortonne, JP ;
Ballotti, R .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (02) :694-702
[3]   Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma [J].
Bloom, MB ;
PerryLalley, D ;
Robbins, PF ;
Li, Y ;
ElGamil, M ;
Rosenberg, SA ;
Yang, JC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) :453-459
[4]   Modeling DNA sequence-based cis-regulatory gene networks [J].
Bolouri, H ;
Davidson, EH .
DEVELOPMENTAL BIOLOGY, 2002, 246 (01) :2-13
[5]   Interaction among SOX10 PAX3 and MITF, three genes altered in Waardenburg syndrome [J].
Bondurand, N ;
Pingault, V ;
Goerich, DE ;
Lemort, N ;
Sock, E ;
Le Caignec, C ;
Wegner, M ;
Goossens, M .
HUMAN MOLECULAR GENETICS, 2000, 9 (13) :1907-1917
[6]   The transcription factor Sox10 is a key regulator of peripheral glial development [J].
Britsch, S ;
Goerich, DE ;
Riethmacher, D ;
Peirano, RI ;
Rossner, M ;
Nave, KA ;
Birchmeier, C ;
Wegner, M .
GENES & DEVELOPMENT, 2001, 15 (01) :66-78
[7]   STRUCTURE OF THE MOUSE TYROSINASE-RELATED PROTEIN-2 DOPACHROME TAUTOMERASE (TYRP2/DCT) GENE AND SEQUENCE OF 2 NOVEL SLATY ALLELES [J].
BUDD, PS ;
JACKSON, IJ .
GENOMICS, 1995, 29 (01) :35-43
[8]   SEQUENCE OF THE HUMAN DOPACHROME TAUTOMERASE-ENCODING TRP-2 CDNA [J].
CASSADY, JL ;
STURM, RA .
GENE, 1994, 143 (02) :295-298
[9]   Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II):: therapeutic implications [J].
Chu, W ;
Pak, BJ ;
Bani, MR ;
Kapoor, M ;
Lu, SJ ;
Tamir, A ;
Kerbel, RS ;
Ben-David, Y .
ONCOGENE, 2000, 19 (03) :395-402
[10]  
CIMENT G, 1990, COMMENTS DEV NEUROBI, V1, P207